Fintiv Rule

Apple v. Fintiv (PTAB 2020, designated precedential) established a six-factor balancing test for discretionary denial of inter partes review (IPR) institution under 35 U.S.C. § 314(a). The PTAB uses these factors to determine whether instituting an IPR would be an inefficient use of PTAB resources given that a parallel district court case is pending. BACKGROUND: the PTAB has discretion under § 314(a) to deny institution even when a petition meets the 'reasonable likelihood' threshold; Fintiv codified the factors the PTAB considers when a parallel district court case is ongoing; POLICY: Fintiv reflects the concern that IPR proceedings can become inefficient and burdensome when the district court will likely reach a trial verdict before the PTAB reaches a final written decision; if the district court resolves the dispute first, the IPR may be mooted or create unnecessary complexity; IMPACT: Fintiv has been highly controversial; patent owners use it to oppose institution when trial is near; petitioners argue Fintiv improperly expands the PTAB's discretion beyond what Congress intended; 2022 DIRECTOR GUIDANCE: USPTO Director Vidal issued Guidance on Discretionary Denial (2022) that narrowed Fintiv's scope: compelling merit petitions (strong unpatentability showing) should be instituted even if Fintiv factors counsel otherwise; the Director also clarified that speculative future trial dates receive less weight.

The Apple v. Fintiv framework directs the PTAB to consider six factors holistically, with no single factor determinative: FACTOR 1 — WHETHER THE COURT GRANTED OR IS LIKELY TO GRANT A STAY: if the district court has granted a stay pending IPR, this factor strongly favors institution; if the district court is likely to grant a stay, this also favors institution; FACTOR 2 — PROXIMITY OF THE TRIAL DATE: if trial is scheduled less than 6 months away, this strongly disfavors institution; if trial is 18+ months away (or the date is uncertain), this favors institution; courts often look at median time-to-trial in the relevant district; FACTOR 3 — INVESTMENT IN THE PARALLEL PROCEEDING: the PTAB and parties' investment in the parallel proceeding is assessed; early stages of the district court case (contentions only) favor institution; advanced stages (after Markman, in discovery) disfavor institution; FACTOR 4 — OVERLAP BETWEEN IPR AND DISTRICT COURT PROCEEDINGS: if the IPR challenges exactly the same claims on the same grounds as the district court invalidity contentions, this disfavors institution (redundancy concern); if the IPR targets distinct claims or distinct grounds, less overlap → favors institution; THE SOTERA STIPULATION ADDRESSES THIS FACTOR: if the petitioner stipulates not to assert in district court the IPR's § 102/103 grounds, the overlap concern is eliminated; FACTOR 5 — WHETHER PETITIONER AND DEFENDANT ARE THE SAME PARTY: if the IPR petitioner is the same party as the accused infringer in district court (the typical case), this disfavors institution (same party already has another forum); third-party petitioners (not parties to the litigation) receive favorable weight on this factor; FACTOR 6 — OTHER CIRCUMSTANCES THAT IMPACT EFFICIENCY OR MERIT: catch-all for case-specific facts; strength of the petition's invalidity showing; nature of the patent (crowded vs. pioneering technology); evidence of patent misuse.

The Sotera stipulation (named after Sotera Wireless, Inc. v. Masimo Corp., PTAB 2020) is a commitment made by the IPR petitioner not to assert in district court the same grounds (or grounds reasonably could have been raised) as those asserted in the IPR petition. HOW IT ADDRESSES FINTIV: Factor 4 (overlap) is the factor most frequently used to deny institution when the district court invalidity contentions mirror the IPR petition; by stipulating to not assert those overlapping grounds in district court, the petitioner eliminates the overlap concern that Factor 4 addresses; additionally, Factor 6 (other circumstances) weighs the stipulation favorably — it ensures the IPR doesn't duplicate district court work; SCOPE: a FULL Sotera stipulation covers all grounds raised and all grounds 'reasonably could have been raised' in the IPR — which is the same scope as § 315(e)(2) estoppel; by offering the stipulation voluntarily, the petitioner shows willingness to be bound by estoppel-equivalent consequences; PARTIAL vs. FULL: some petitioners offer a narrower stipulation (only the specific grounds in the petition, not all that 'could have been raised'); PTAB scrutinizes partial stipulations and may give them less weight; WHEN TO USE: always include a Sotera stipulation when the district court invalidity contentions overlap significantly with the IPR petition grounds; the stipulation is typically included in the IPR petition itself or in a reply to the patent owner's POPR; WHAT IT DOESN'T FIX: Sotera doesn't directly address Factor 2 (trial date) — if trial is imminent, Fintiv may still counsel denial even with a full Sotera stipulation; Factor 2 remains the most significant factor when trial is less than 6–12 months away.

In June 2022, USPTO Director Kathi Vidal issued guidance that significantly narrowed how Fintiv is applied: KEY CHANGES IN THE 2022 GUIDANCE: (1) COMPELLING MERITS EXCEPTION: if a petition presents a compelling, meritorious case for unpatentability — essentially, if the invalidity showing is exceptionally strong — the PTAB should institute even if Fintiv factors otherwise counsel denial; this addresses the concern that strong invalidity cases were being denied due to timing rather than merit; the Director articulated a 'compelling' standard as higher than 'reasonable likelihood' but not as high as 'preponderance of the evidence'; (2) DISTRICT COURT SCHEDULES: the Director clarified that when a district court trial schedule is uncertain or based on an older scheduling order, the PTAB should not give significant weight to a trial date that may not actually occur; speculative or routinely-postponed trial dates receive less weight on Factor 2; (3) SOTERA WEIGHT: the Director confirmed that a full Sotera stipulation substantially mitigates Factor 4 overlap concerns and, in some cases, Factor 6; (4) DISCRETION RETAINED: the Director's guidance did not eliminate Fintiv — the PTAB still has discretion to deny; the guidance narrows when that discretion should be exercised; DIRECTOR REVIEW: the AIA provides for Director review of PTAB decisions; Director Vidal used this authority to reconsider several Fintiv-based denials; the Director review mechanism provides an additional challenge avenue when petitioners believe Fintiv was improperly applied; ONGOING CONTROVERSY: patent owners argue the 2022 guidance went too far in restricting Fintiv; petitioners argue it still doesn't go far enough; the tension reflects ongoing policy debate over the PTAB's role relative to district courts.

Overcoming Fintiv requires addressing each factor proactively in the petition and parallel motion practice: FACTOR 1 (STAY LIKELIHOOD): file a motion to stay the district court case at the same time as the IPR petition; if the district court grants the stay, Factor 1 strongly favors institution; even a pending stay motion shows the petitioner is seeking to coordinate; FACTOR 2 (TRIAL DATE): file the IPR petition as early as possible within the § 315(b) one-year window; the earlier the petition, the further the trial date likely is at the time of PTAB institution; show that the trial date in the relevant venue is statistically uncertain (e.g., WDTX median time to trial exceeds 20 months); if the patent owner delayed serving the complaint to manipulate the filing window, note that the effective trial date is not imminent from the petition filing date perspective; FACTOR 4 (OVERLAP): include a full Sotera stipulation in the petition or in a reply to the POPR; differentiate IPR grounds from district court invalidity contentions where possible (e.g., IPR challenges § 102/103 on prior art; district court focuses on § 101 and § 112); FACTOR 6 (COMPELLING MERITS): present the strongest possible invalidity case; include a clear, well-supported expert declaration (§ 1.37 CFR); the Director's guidance gives 'compelling merits' the ability to override even unfavorable Fintiv factors; cite the 2022 Director Guidance explicitly in the petition; INSTITUTION REPLY: in the reply to the POPR, directly address each Fintiv factor raised by the patent owner; update the trial date status (trial dates often get continued); provide evidence of stay motion outcome if any; PTAB SERIAL PETITIONS: be cautious about follow-on petitions targeting the same claims — the PTAB may use Fintiv/General Plastic factors to deny serial petitions even without a compelling merits exception.